What FDA Approvals Reveal About Brand Name Risk
Most approved drug names still show similarity conflicts.
The difference isn’t eliminating risk—it’s how that risk is managed.
Based on analysis of 100 FDA-approved brand names and emerging biosimilar naming pressure.
100 FDA-approved brand names analyzed
33 therapeutic categories represented
Majority show similarity comparators
Biosimilars driving increased naming pressure
What this report actually shows
- Why similarity does not automatically lead to rejection
- How regulators evaluate naming risk in practice
- Where naming strategies are converging
- How biosimilars are increasing naming pressure
- What approved names reveal about real-world decision-making
Key patterns from 2025 approvals
- Similarity is the baseline: Most approved names still show similarity flags—approval depends on context, not perfection.
- Approval = managed risk: Regulators assess total risk across clinical, linguistic, and usage factors.
- Names are signaling tools: Some approved names subtly communicate indication, mechanism, or dosage.
- Increasing naming pressure: Biosimilars and crowded therapeutic classes are tightening the naming landscape.
Why this matters for your next submission
If you’re developing brand names today, the challenge isn’t avoiding similarity—it’s understanding how much similarity is acceptable and in what context.
This report provides a practical view of how approved names navigate that balance.
See what approvals actually show
A practical look at naming risk, similarity, and strategy across 100 FDA-approved brand names.
Brandsymbol All rights reserved © 2026